Fear of Adverse Drug Reactions (ADRs) to HAART among Adult HIV/AIDS Patients in FMC, Makurdi, North Central, Nigeria

Fear of Adverse Drug Reactions (ADRs) to HAART among Adult HIV/AIDS Patients in FMC, Makurdi, North Central, Nigeria

Loading document ...
Loading page ...


Author(s): Samuel Olusegun Itodo, Paul O. Okonkwo, Asalu Adedayo, Emmanuel Olumuyiwa Onifade, Nwoke Obinna Chidubem, Stephen Olaide Aremu, Onyekachi Ezekiel Ekowo, Anonde Chinedu Matthew, Joseph Aondowase Mamfe

Download Full PDF Read Complete Article

DOI: 10.18483/ijSci.2549 24 60 39-45 Volume 11 - Feb 2022


Aim and Objective: To evaluate the fear of ADRs to HAART among adult HIV patients who enrolled in free HIV care in Makurdi, Northcentral, Nigeria. Methodology: The study was conducted among adult naive HIV-positive patients attending HIV clinic at Federal Medical Centre (FMC), Makurdi, Northcentral, Nigeria. We employed structured questionnaires and records from patients’ folders and databases to obtain appropriate information (gathered by experts who were key-informant interviewers in conjunction with trained HIV counselors) about the various types of fears exhibited by adult HIV patients at the initiation of ART. Study participants were drawn from the population of People Living with HIV/AIDS (PLWHA) in Makurdi and its environs using 150 recruited patients. Results: Of the 150 respondents who participated in the study, forty (40) were males (M) and one hundred and ten (110) were females (F); ratio1M/2.75F. The majority of the respondents were in the low socio-economic class (62%). While 31.3% of the respondents stopped at secondary school level, 33.3% of them had post-secondary education. Fear ADRs to HAART was reported by 19(12.67%) patients. This was only superseded by fears related to both the direct and indirect cost of treatment, majorly the fear of not having enough money to maintain self while on ARVs, 39 (26%) and the fear of inability to pay their children’s school fees, 29(19.33%). Conclusion: The study revealed that fear of ADRs to HAART, apart from fear of stigmatization and the psychological trauma accompanying this illness, is being expressed by HIV-positive patients. This could be a major barrier to enrolment into free HIV care services among PLWHA. Further studies, therefore, may be needed in this area to ascertain the contribution of fear of ADRs to HAART as barrier to enrolment. Health care providers (HCPs) should help allay the fear of ADRs to HAART among PLWHA to achieve optimum enrolment into free HIV/AIDS care in Makurdi.


Anti-retroviral Drugs, People living with HIV/AIDS (PLWHA), Clients Fear, HIV Patients, Barriers, Middle Belt


  1. Becker, S. (2004). Liver toxicity in epidemiological cohorts. Clinical Infectious Diseases. 38:549-55
  2. Beer, L., Fagan, J., Valverde, E. and Bertolli, J. (2009). “Health-related beliefs and decisions about accessing HIV medical care among HIV-infected persons who are not receiving care,” AIDS Patient Care and STDs, vol. 23, no. 9, pp. 785–792. View at: Publisher Site | Google ScholarBertram, G. and Anthony, J. (2015). Antiviral Agents. Basic and Clinical Pharmacology (13th edition). McGraw Hill Education. Page 842 – 849.
  3. Bhuvana, K, Hema, N. and Sangeetha. (2014). A prospective observational study of adverse drug reactions to antiretroviral therapy: type and risk factors in a tertiary care teaching hospital. Int J Basic ClinPharmacol.3 (2): 380-384. DOI: 10.5455/2319-2003.ijbcp20140425.
  4. Bwambale, F., Sali, S., Byaruhanga, S., Kalyango, J., and Karamagi, C. (2008). Voluntary HIV counselling and testing among men in rural western Uganda: implications for HIV prevention. BMCPublic Health. 8: 263.
  5. Charles, B., Pedro, C., David, A., Sharon, L., Christine, K., Bonaventura, C., Adriano, L., Margaret, A., Dietmar, N., Douglas, M., and Hernan, V. (2006). Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug resistant patients with Tipranavir (RESIST) studies: an analysis of combined data from analysis of combined data from two randomised open-label trials. The Lancet.368 (9534): 466-475. https://doi.org/10.1016/S0140-6736(06)69154-X
  6. Felix, G. and Ceolim, M. (2012). The profile of women with HIV/AIDS and their adherence to xccq`antiretroviral therapy. Rev Esc Enfern USP (internet). 46(4): 884-91. Available from: http://www.scielo.br/pdf/reeusp/v46n4/en-15. Pdf.
  7. FMoH (2016). Federal Ministry of Health. National guidelines for HIV prevention treatment and control. National AIDS and STIs Control Programme. Abuja, Nigeria.
  8. Gertrude, N., Lynn, A., Moses, K., Fredrick, E., Larry, W., Neema, N., Godfrey, K., Fred, N., Valerian, K., David, S., Maria, W., and Ronald, G. (2013). A Qualitative Study of Barriers to Enrollment into Free HIV Care: Perspectives of Never-in-Care HIV-Positive Patients and Providers in Rakai, Uganda. BioMed Research International. Article ID 470245 | 7 pages | https://doi.org/10.1155/2013/470245
  9. Gilbert, L. and Walker, L. (2010). “‘My biggest fear was that people would reject me once they knew my status...’: stigma as experienced by patients in an HIV/AIDS clinic in Johannesburg, South Africa,” Health and Social Care in the Community, vol. 18, no. 2, pp. 139–146. View at: Publisher Site | Google Scholar
  10. Lut, V., Amy, C., Khatija, A., Kawango, A., Johan, L., Saidi, K., Mookho, M., Fredrick, O., Rachel, M., Jacob, O., Lucky, T., Modie, C. M., Paul, M., Mankalimeng, M., Ilse, R., Shumani, E. M., Lisa, S., Haddie, K., Stella, K., Christina, W., Robert, G., Angela, K., Kavita, N., Justin, M., Katrien, F., Jennifer, D., Tania, C., Timothy, D., Douglas, T. and FEM-PrEP Study Group (2012). Preexposure Prophylaxis for HIV Infection among African Women. The New England journal of medicine, 367(5): 411–422. https://doi.org/10.1056/NEJMoa1202614
  11. Miriam, R., Wafaa, E., David, A., Joia, M., Henry, M., Peter, M., Paulay, M., and Janet, C. (2002). Antiretroviral treatment in resource-poor settings: clinical research priorities. Lancet.11/09/2002; 360 (9344): 165-79. https:// doi.org/10.1016/S0140-6736(02)11478-4
  12. Nadkar, M. Y., and Bajpai, S. (2009). Antiretroviral therapy: toxicity and adherence. JAPI. 57: 375 – 376.
  13. NPC. (2006). National Population Commission of Nigeria (web). National Bureau of Statistics. https://www.citypopulation.de/php/nigeria-admin.php?adm2id=NGA007013. [Accessed on March 21, 2016].
  14. Powell-Cope, G., White, J., Henkelman, E., and Turner, B. (2003). Qualitative and quantitative assessments of HAART adherence of substance-abusing women. AIDS Care. 15: 239 – 249.
  15. Rujumba, J., Neema, S., Byamugisha, R., Tylleskär, T., Tumwine, J. K. and Heggenhougen, H. K. (2012). Telling my husband I have HIV is too heavy to come out of my mouth’: pregnant women's disclosure experiences and support needs following antenatal HIV testing in eastern Uganda,” Journal of the International AIDS Society, 15 (2), 17429.
  16. Shiana, O., Rehle, T., Simbayi, L., Zuma, K., Jooste, S., Zungu, N. and Labadarios, D. (2014.). South African National HIV Prevalence, Incidence and Behaviour Survey; Human Sciences Research Council: Cape Town, South Africa.
  17. Sayles, J., Wong, M., Kinsler, J., Martins, D. and Cunningham, W. (2009). “The association of stigma with self-reported access to medical care and antiretroviral therapy adherence in persons living with HIV/AIDS,” Journal of General Internal Medicine, 24 (10): 1101 – 1108. View at: Google Scholar
  18. Tumwine, J. and Heggenhougen, H. (2012). “Telling my husband I have HIV is too heavy to come out of my mouth”: pregnant women’s disclosure experiences and support needs following antenatal HIV testing in eastern Uganda. J Int AIDS Soc. 15: 17429.
  19. UNAIDS, (2014). UN Joint Programme on HIV/AIDS (UNAIDS). The GAP Report2. Available online:http://www.refworld.org/docid/53flel604.html (Accessed on 20 February 2017)
  20. .UNAIDS, (2018). UN Joint Programme on HIV/AIDS (UNAIDS). Global HIV & statistics ---2018 Fact sheet. Available on line: http//www.unaids.org/en/resources/fact-sheet.
  21. Weiss, M., Ramakrishna,J. and Somma, D. (2006). “Health-related stigma: rethinking concepts and interventions,” Psychology, Health and Medicine, 11, (3), 277 – 287.
  22. WHO (2002). The use of antiretroviral therapy: a simplified approach for resource-constrained countries: World Health Organization.
  23. WHO (2013). UNICEF and UNAIDS (2013). Global update on HIV treatment 2013: results, impactand opportunities summary. http://www. who.int/hiv/pub/progressreports/update2013/en/. Accessed 7 July 2015.
  24. WHO (2020). https://www.who.int/news-room/fact-sheet/details/hiv-aids (Accessed on 31st March, 2021).

Cite this Article:

International Journal of Sciences is Open Access Journal.
This article is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) License.
Author(s) retain the copyrights of this article, though, publication rights are with Alkhaer Publications.

Search Articles

Issue June 2023

Volume 12, June 2023

Table of Contents

World-wide Delivery is FREE

Share this Issue with Friends:

Submit your Paper